Trials / Completed
CompletedNCT05681819
Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.
A Phase Ib, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1707 | Multiple-ascending Dose |
| DRUG | SHR-1707 placebo | Multiple-ascending Dose |
Timeline
- Start date
- 2023-02-17
- Primary completion
- 2024-05-18
- Completion
- 2025-07-18
- First posted
- 2023-01-12
- Last updated
- 2025-08-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05681819. Inclusion in this directory is not an endorsement.